Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for eosinophilic otitis media in patients with chronic rhinosinusitis with nasal polyps
NL-OMON60713Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic otitis media (EOM) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in otologic questionnaire scores. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)eosinophilic otitis media (EOM)
Beyond the preview
Go deeper on NL-OMON60713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60713.